Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

Bibliografiska uppgifter
Huvudupphovsmän: Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K
Materialtyp: Conference item
Publicerad: BMJ Publishing Group Limited 2018
_version_ 1826266654262165504
author Nash, P
Coates, L
Kivitz, A
Mease, P
Gladman, D
Covarrubias-Cobos, J
Fleishaker, D
Wang, C
Kudlacz, E
Menon, S
Fallon, L
Hendrikx, T
Kanik, K
author_facet Nash, P
Coates, L
Kivitz, A
Mease, P
Gladman, D
Covarrubias-Cobos, J
Fleishaker, D
Wang, C
Kudlacz, E
Menon, S
Fallon, L
Hendrikx, T
Kanik, K
author_sort Nash, P
collection OXFORD
description
first_indexed 2024-03-06T20:42:13Z
format Conference item
id oxford-uuid:34a929e9-eee5-4bfc-ab8d-f37def274b76
institution University of Oxford
last_indexed 2024-03-06T20:42:13Z
publishDate 2018
publisher BMJ Publishing Group Limited
record_format dspace
spelling oxford-uuid:34a929e9-eee5-4bfc-ab8d-f37def274b762022-03-26T13:27:22ZSafety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension studyConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:34a929e9-eee5-4bfc-ab8d-f37def274b76Symplectic Elements at OxfordBMJ Publishing Group Limited2018Nash, PCoates, LKivitz, AMease, PGladman, DCovarrubias-Cobos, JFleishaker, DWang, CKudlacz, EMenon, SFallon, LHendrikx, TKanik, K
spellingShingle Nash, P
Coates, L
Kivitz, A
Mease, P
Gladman, D
Covarrubias-Cobos, J
Fleishaker, D
Wang, C
Kudlacz, E
Menon, S
Fallon, L
Hendrikx, T
Kanik, K
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
title Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
title_full Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
title_fullStr Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
title_full_unstemmed Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
title_short Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
title_sort safety and efficacy of tofacitinib an oral janus kinase inhibitor up to 36 months in patients with active psoriatic arthritis data from the third interim analysis of opal balance an open label long term extension study
work_keys_str_mv AT nashp safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT coatesl safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT kivitza safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT measep safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT gladmand safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT covarrubiascobosj safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT fleishakerd safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT wangc safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT kudlacze safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT menons safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT fallonl safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT hendrikxt safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy
AT kanikk safetyandefficacyoftofacitinibanoraljanuskinaseinhibitorupto36monthsinpatientswithactivepsoriaticarthritisdatafromthethirdinterimanalysisofopalbalanceanopenlabellongtermextensionstudy